Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Oct;27(5):703-711.
doi: 10.1177/1591019921996100. Epub 2021 Feb 18.

Safety and efficacy of Angio-Seal device for transfemoral neuroendovascular procedures: A systematic review and meta-analysis

Muhammed Amir Essibayi  1 , Harry Cloft  2 , Luis E Savastano  1 , Waleed Brinjikji  1   2
Affiliations
Meta-Analysis

Safety and efficacy of Angio-Seal device for transfemoral neuroendovascular procedures: A systematic review and meta-analysis

Muhammed Amir Essibayi et al. Interv Neuroradiol. 2021 Oct.

Abstract

Introduction: Angio-Seal is a commonly used device for femoral hemostasis in neuroendovascular procedures. This meta-analysis investigates of the safety and efficacy of Angio-Seal in patients undergoing endovascular neurointerventional procedures.

Methods: A systematic review and meta-analysis on all studies evaluating the Angio-Seal device in neurointerventional procedures from inception through 2020 were performed. We studied rates of groin hematoma, retroperitoneal hematoma, pseudoaneurysm, ipsilateral DVT, and ischemic complications. Meta-analysis was performed using the random-effects model.

Results: 13 studies were included in our analysis. 2250 patients with 104 complications were found {4.5% (95% CI, 2.7%-6.3%)}. Of these complications, groin hematoma was the most common with a rate of 2.4% (95% CI, 1.1%-3.6%). Retroperitoneal hematoma {0.3% (95% CI, 0%-0.5%)}, pseudo-aneurysm {0.5% (95% CI, 0.2%-0.8%), and ipsilateral DVT {0.3% (95% CI, 0.1%-0.7%) were also not in negligible rate. The rate of other complications were as follows: vessel occlusion/stenosis; 0.2% (95% CI, 0%-0.4%), vascular surgery; 0.2% (95% CI, 0%-0.5%), and infection; 0.2% (95% CI, 0%-0.5%). One patient died as result of hemorrhagic complications {0.1% (95% CI, 0%-0.3%)}. Use of anticoagulant/antiplatelet therapy was found to be positively correlated with high risk of any groin complication and groin hematoma (p ≤ .05). Female gender was associated with high risk of ipsilateral DVT (p ≤ .05). Interestingly, large sheath size was associated with low risk of groin hematoma (p ≤ .05).

Conclusion: The safety and efficacy rate of Angio-Seal was approximately 95%. The most common complication was groin hematoma. Serious complications including retroperitoneal hematoma and femoral artery occlusion were rare.

Keywords: Angio-Seal; transfemoral access; transradial access; vascular closure devices.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
The Flow diagram of study selection process.
Figure 2.
Figure 2.
Forest plots with random-effect model demonstrate the risk of following complications after use of Angio-Seal closure device in transfemoral neuroendovascular procedures; (a) Overall Groin complication. (b) Groin hematoma. (c) Retroperitoneal hematoma. (d) Pseudoaneurysm formation. (e) Ipsilateral DVT. (f) Vascular surgery. (g) vascular occlusion/stenosis. (h) Infection. (i) Complication-associated mortality.
Figure 2.
Figure 2.
Forest plots with random-effect model demonstrate the risk of following complications after use of Angio-Seal closure device in transfemoral neuroendovascular procedures; (a) Overall Groin complication. (b) Groin hematoma. (c) Retroperitoneal hematoma. (d) Pseudoaneurysm formation. (e) Ipsilateral DVT. (f) Vascular surgery. (g) vascular occlusion/stenosis. (h) Infection. (i) Complication-associated mortality.
See this image and copyright information in PMC

References

    1. DerSimonian R, Laird N.Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188. - PubMed
    1. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557–560. - PMC - PubMed
    1. The jamovi project. jamovi (Version 1.2) [Computer Software]. https://www.jamovi.org (2020, accessed February 2021)
    1. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012; 49: 1–15.
    1. Deeks JJ, Higgins JPT, Altman DG. (eds). Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT and Green S (eds) Cochrane handbook for systematic reviews of interventions (Version 5.1.0). London: The Cochrane Collaboration, 2011. pp. 9.33–9.34.

LinkOut - more resources